Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.

It is important to develop tools to predict how patients are going to react to treatments, explains Stephenson. This can help the patient’s quality of life and equip them with the knowledge to make a well-informed decision regarding their treatment. Additionally, this can lead to higher rates of patient satisfaction, states Stephenson.

Videos

Dr. Stephenson on the Development of Biomarkers for Prostate Cancer

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses advancements being made in the field of prostate cancer.

A challenge that needs to be addressed is the ability to determine which cancers will be aggressive and require a more intense treatment, explains Stephenson. There are a lot of developments in the areas of imaging, genomics, and biomarkers that will help to answer this question.

Additionally, for men with more aggressive cancers, there are emergences of new treatment paradigms, states Stephenson.

Dr. Stephenson on Advancements of Treatment for Prostate Cancer

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.

According to Stephenson, this is an important study for both clinicians and patients to understand the impact of treatment on the quality of life for patients with localized prostate cancer.

Dr. Stephenson on the Significance of a Study on Localized Prostate Cancer

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer. 

This is the first comparative study among 4 different treatments, explains Stephenson. This gives patients information regarding what to expect over the next 2 years with each treatment option. 

According to Stephenson, it is important to balance the cancer control so as not to jeopardize a patient’s curability at the expense of quality of life.  

Dr. Stephenson on 2 Years Following the Management of Localized Prostate Cancer

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic discusses urinary, bowel, and sexual function following the management of localized prostate cancer.

Although there are many ways to achieve high cure rates for patients with prostate cancer, there are still potential impacts on the quality of life, states Stephenson.

Active surveillance has been used as a treatment strategy to differ treatment and therefore the side effects of treatment, to give patients the highest likelihood that they will preserve their quality of life.

Andrew J. Stephenson, MD

Articles

Dr. Stephenson on the Development of Biomarkers for Prostate Cancer

Dr. Stephenson on Advancements of Treatment for Prostate Cancer

Dr. Stephenson on the Significance of a Study on Localized Prostate Cancer

Dr. Stephenson on 2 Years Following the Management of Localized Prostate Cancer

Dr. Stephenson on the Quality of Life Following the Management of Localized Prostate Cancer